Drugs.com - Clinical Trials

ESSENCE Phase 3 Trial of Semaglutide Showed Significant Improvements at 72 Weeks in Adults with MASH, Published in NEJM

PLAINSBORO, N.J., April 30, 2025 /PRNewswire/ -- Today, The New England Journal of Medicine (NEJM) published results from part 1 of the ongoing phase 3 ESSENCE trial which investigated the effects of once-weekly subcutaneous semaglutide 2.4 mg on...

May 5, 2025 - 08:28
 0
ESSENCE Phase 3 Trial of Semaglutide Showed Significant Improvements at 72 Weeks in Adults with MASH, Published in NEJM
PLAINSBORO, N.J., April 30, 2025 /PRNewswire/ -- Today, The New England Journal of Medicine (NEJM) published results from part 1 of the ongoing phase 3 ESSENCE trial which investigated the effects of once-weekly subcutaneous semaglutide 2.4 mg on...
Read More

Tags:

Previous Article

FDA Accepts Filing Application for Oral Semaglutide 25 mg, Which If Approved, Wo...

Next Article

Spanish electricity blackout drives use of Musk’s Starlink

Related Posts

Boehringer’s New Zongertinib Data Demonstrates Durable and Clinically Meaningful Results in Patients with HER2 (ERBB2)-Mutant Advanced NSCLC

Boehringer’s New Zongertinib Data Demonstrates Durable ...

Apr 30, 2025  0

Johnson & Johnson’s TAR-200 Monotherapy Demonstrates Highest Complete Response Rate with Sustained Clinical Benefits in Patients with Certain Types of Bladder Cancer

Johnson & Johnson’s TAR-200 Monotherapy Demonstrates Hi...

Apr 30, 2025  0

Immunovant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies

Immunovant Announces Positive Results for Batoclimab My...

Apr 26, 2025  0